Royalty Pharma (RPRX) opened 2026 with Q1 revenue of US$631 million and basic EPS of US$0.69, alongside trailing twelve month revenue of about US$2.4 billion and EPS of US$1.93 that sit against a net profit margin of 33.9%. Over recent quarters the company has seen revenue move from US$568 million in Q1 2025 to US$631 million in Q1 2026, while quarterly EPS has ranged between US$0.07 and US$0.69. This sets up a results snapshot where forecast revenue and earnings growth meet a thinner margin profile that investors may want to watch closely.

See our full analysis for Royalty Pharma.

With the latest figures on the table, the next step is to see how these results line up against the widely followed narratives about Royalty Pharma’s growth potential, risk profile, and profitability trend.

Margins Step Down From 48.3% To 33.9%

• On a trailing basis, net profit margin is 33.9%, compared with 48.3% a year earlier, while trailing net income sits at about US$826.9 million on roughly US$2.4b of revenue.
• Bears argue that shrinking margins and higher financing costs could squeeze returns, and the current spread between the 33.9% margin and past five year earnings growth of 11.7% a year is often cited as support for that view.
  • The concern is that a richer P/E of 27.2x and relatively high debt levels could leave less room to absorb further margin pressure if royalty receipts soften.
  • At the same time, forecast earnings growth of about 8.1% a year suggests bears are not expecting a collapse. The key question is whether margins stabilize above, or continue to drift away from, last year’s 48.3% level.

Skeptics watching the drop in net margin may want to see how the cautious case lines up with the full bearish narrative before deciding what it means for long term returns. 🐻 Royalty Pharma Bear Case

Revenue Near US$2.4b, Growth Forecast Around 15.5%

• Over the last twelve months, revenue is about US$2.4b, and analysts are forecasting around 15.5% annual revenue growth, which is higher than the 11.3% forecast for the broader US market.
• Supporters of the bullish view point to this faster revenue trajectory as backing their argument that Royalty Pharma can keep growing its royalty base, yet the same data also shows earnings are only projected to grow about 8.1% a year, which is lower than the wider market’s 16.1% forecast.
  • The bullish narrative leans on portfolio expansion and new royalty deals as drivers of future receipts, which lines up with the 15.5% revenue growth forecast in the data.
  • However, the gap between revenue and earnings growth, combined with trailing margins slipping from 48.3% to 33.9%, means bulls are counting on volume growth to offset pressure on profitability per dollar of revenue.

If you want to see how bullish investors connect these revenue forecasts to their long term thesis, it is worth reading the dedicated bull case and checking how it stacks up against the latest numbers. 🐂 Royalty Pharma Bull Case

P/E Of 27.2x Versus Peers, DCF Fair Value Much Higher

• The stock trades on a trailing P/E of 27.2x compared with a 20.2x peer average and 16.8x for the US pharmaceuticals industry, while a DCF fair value of about US$187.37 sits well above the current share price of US$50.69.
• Consensus narrative highlights the tension here, with one side of the data flagging richer earnings multiples than peers and the other side showing a DCF fair value that is more than 3x the current price.
  • On one hand, the higher P/E ratio alongside a 1.85% dividend that is not well covered by free cash flow, plus elevated debt and recent insider selling, are all factors that can make the valuation look demanding.
  • On the other, forecast revenue growth of 15.5% a year and earnings growth of about 8.1% a year are part of the reason a DCF model points to US$187.37, so the spread between that figure and US$50.69 is something investors often focus on when they compare different valuation methods.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Royalty Pharma on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With sentiment split between pressure on margins and support from revenue forecasts, it makes sense to review the data yourself and decide where you stand. If you want a clearer view of how risks and rewards balance out for Royalty Pharma, take a look at the 2 key rewards and 3 important warning signs.

See What Else Is Out There

Royalty Pharma pairs a 33.9% net margin and trailing P/E of 27.2x with relatively high debt, a thinly covered dividend, and moderating earnings growth forecasts.

If you are concerned about that mix of leverage, coverage, and valuation risk, it makes sense to compare it with companies screened for 74 resilient stocks with low risk scores that aim to keep potential downside in check.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.